Welcome to our dedicated page for Revolution Medicines SEC filings (Ticker: RVMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Revolution Medicines, Inc. filings document a late-stage clinical oncology company focused on RAS-addicted cancers and RAS(ON) inhibitors. Its Form 8-K reports include financial results, clinical-program updates for daraxonrasib and other pipeline candidates, regulatory-related disclosures and material events tied to corporate progress.
The company’s SEC record also covers proxy governance, annual meeting matters, executive compensation, registered securities and capital-structure changes. Disclosures identify Nasdaq-listed common stock and warrants, and material-agreement filings describe convertible senior notes due 2033, related indenture terms and other financing arrangements used to support research and development, administrative expenses and potential commercialization activities.
Revolution Medicines, Inc. Chief Medical Officer Wei Lin reported an open-market sale of 2,073 shares of common stock on March 17, 2026 at an average price of $99.4804 per share. The transaction was made under a pre-arranged Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy tax withholding obligations upon the vesting of restricted stock units after March 15, 2025. Following this sale, Lin holds 101,366 shares directly, which the disclosure states includes 62,050 restricted stock units.
Revolution Medicines, Inc. officer Stephen Michael Kelsey reported an open-market sale of 4,302 shares of Common Stock at 99.4804 per share. The transaction was made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy tax withholding obligations upon vesting of restricted stock units. After this sale, he directly owns 295,398 shares, which includes 84,250 restricted stock units.
Revolution Medicines director Mark A. Goldsmith sold 12,871 shares of common stock in an open-market transaction at an average price of $99.4804 per share on March 17, 2026. The sale was made under a Rule 10b5-1 instruction letter to satisfy tax withholding obligations from vesting restricted stock units.
After the sale, he holds 276,698 shares directly, including 201,150 RSUs. He also has indirect holdings through trusts, with reported positions of 594,060, 64,424, and 64,424 shares of common stock held in separate revocable trusts.
Revolution Medicines, Inc. Chief Operating Officer Margaret A. Horn reported an open-market sale of 4,583 shares of common stock at an average price of $99.4804 per share. After this transaction, she directly holds 157,570 shares. A footnote states the sale was executed under a Rule 10b5-1 instruction letter to satisfy tax withholding obligations related to vesting restricted stock units.
Revolution Medicines, Inc. Chief Financial Officer Anders Jack reported an open-market sale of 2,753 shares of common stock at an average price of $99.4804 per share. The transaction was made pursuant to a pre-established Rule 10b5-1 instruction letter to satisfy tax withholding obligations on vested RSUs. Following the sale, he directly holds 125,512 shares, which include 56,600 restricted stock units.
Revolution Medicines General Counsel Jeff Cislini reported selling 2,958 shares of common stock in two open-market transactions. On March 17, he sold 1,795 shares at $99.4804 per share, and on March 19 he sold 1,163 shares at $97.44 per share. One sale was made under a Rule 10b5-1 instruction letter related to tax withholding on vested RSUs, and the other under a 10b5-1 trading plan. After these sales, he directly holds 58,518 shares, including 48,125 RSUs.
Revolution Medicines, Inc. officer Wang Xiaolin reported an open-market sale of 2,010 shares of common stock on March 17, 2026 at an average price of $99.4804 per share. The transaction was executed under a pre-arranged Rule 10b5-1 instruction letter to cover tax withholding on vested RSUs. Following the sale, Wang holds 116,063 shares directly, including 48,700 restricted stock units.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice relating to proposed sales of restricted stock units tied to RVMD stock. The filing lists a sale method and shows prior sales by Jeffrey Todd Cislini of 2,053 shares on 03/16/2026 and 908 shares on 01/21/2026.
RVMD filed a Form 144 reporting a proposed sale of Common Stock. The notice lists restricted stock unit grants dated 03/01/2022, 03/01/2023, 03/01/2024, and 03/01/2025 with line-item amounts shown in the excerpt. The filing is a routine sale notice; timing and proceeds treatment are not provided in the excerpt.
ETRADE Financial Corporation submitted a Form 144 notice reporting Common Stock related to restricted stock unit grants and prospective sales. The excerpt lists grant dates and awarded share counts: 05/01/2023 1,307 shares; 03/01/2024 464 shares; 03/01/2025 517 shares. The filing references NASDAQ and a date of 03/16/2026.